AzTrials
AzTrials

Atrioventricular BlockOPTI-PACSNCT07795541

OPTImizing Lead Placement in Patients Requiring Pacemaker After Cardiac Surgery

A study testing Left bundle branch area pacing and Conventional pacing strategy in people with Atrioventricular Block and Cardiac Surgery, run by Sahlgrenska University Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Conventional right ventricular pacing has been associated with ventricular dyssynchrony and an increased risk of pacing-induced cardiomyopathy, which may lead to worse clinical outcomes. To lessen the burden of pacing-induced cardiomyopathy, the adoption of conduction system pacing has increased in recent years. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atrioventricular Block, Cardiac Surgery
What is being tested?
Left bundle branch area pacing and Conventional pacing strategy
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
110 participants
Where
No sites listed yet
Study dates
10 Sep 2026to Dec 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • High degree atrioventricular block
  • Cardiac surgery within 30 days of pacemaker implantation
  • Written informed consent
  • Current left ventricular ejection fraction at or above 50%

Who cannot join

  • Any concomitant condition that results in a life expectancy of less than 1 year
  • Planned for heart transplant or left ventricular assist device
  • Current dialysis
  • Not suitable according to the opinion of the investigators due to characteristics that interfere with the adherence to the study protocol.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Andreas S Martinsson, MD, PhD contact

+46313427717

andreas.s.martinsson@vgregion.se

Alice David, MD contact

+313429684

laura.david@vgregion.se

About this study

Official title: OPTIMIZING LEAD PLACEMENT IN PATIENTS REQUIRING PACEMAKER AFTER CARDIAC SURGERY

Conventional right ventricular pacing has been associated with ventricular dyssynchrony and an increased risk of pacing-induced cardiomyopathy, which may lead to worse clinical outcomes. To lessen the burden of pacing-induced cardiomyopathy, the adoption of conduction system pacing has increased in recent years. In patients with normal cardiac function, measured as left ventricular ejection fraction, the superiority of conduction system pacing is less clear. As a result, both pacing strategies remain in widespread clinical use.

Patients undergoing cardiac surgery represent a vulnerable cohort for pacing-induced cardiomyopathy, given their established structural heart disease, and postoperative atrioventricular block remains a common occurrence in these patients.

This multicenter randomized trial aims to evaluate the use of conduction system pacing, in the form of left bundle branch area pacing, versus conventional pacing in patients with normal left ventricular ejection fraction after cardiac surgery.

Read the detailed description

A high percentage of ventricular pacing increases the risk of pacing-induced cardiomyopathy. Pacing-induced cardiomyopathy is a syndrome defined by left ventricular dysfunction secondary to chronic right ventricular pacing, resulting in impaired outcomes. Pacing-induced cardiomyopathy is estimated to affect approximately 10-20% of patients with a high proportion of right ventricular pacing (>20%), a population that mainly consists of patients with atrioventricular block (AVB). The abnormal activation leads to prolonged electrical and mechanical activation, which results in ventricular dyssynchrony. Other important risk factors for pacing-induced cardiomyopathy include structural heart disease and reduced ejection fraction, male sex and wide, paced QRS.

Clinical practice guidelines support pacemaker implantation following cardiac surgery only for severe and non-transient bradyarrhythmias, as pacemaker implantation increases the risk of severe infections and device-related long-term complications. Evidence suggests that a substantial proportion of patients who receive a pacemaker following cardiac surgery have limited need for pacing at long-term follow-up. Thus, the risk/benefit ratio for patients following cardiac surgery differs from that of the general population, while these patients also form a vulnerable population at high risk for pacing-induced cardiomyopathy.

Over the last decade, a conduction system pacing strategy called left bundle branch area pacing (LBBAP) has been developed. In LBBAP, the pacemaker lead is inserted deep into the interventricular septum from the right ventricle to the left ventricular endocardium, targeting the left bundle and its resulting fascicles. As the current understanding of the development of pacing-induced cardiomyopathy suggests that the electrical dyssynchrony introduced by right ventricular pacing plays a crucial role, our hypothesis is that its incidence could be reduced by the favorable electrical activation achieved with LBBAP.

There are ongoing randomized controlled trials of conduction system pacing in the general population; however, none are investigating cardiac surgery patients. These patients differ substantially from the general population in age, expected long-term survival, and cardiovascular health. This increases their risk of pacing-induced cardiomyopathy and could influence the feasibility of conduction system pacing due to their otherwise impaired cardiovascular health. At the same time, their long-term pacing dependence could differ from that of the general population.

Therefore, the aim of the present multicenter randomized controlled trial is to evaluate the long-term outcomes of LBBAP versus right ventricular pacing after cardiac surgery in patients with normal left ventricular ejection fraction. A secondary aim is to assess the feasibility of LBBAP after cardiac surgery with regard to implantation success and long-term electrical parameters. The results of this trial are anticipated to provide clinically meaningful evidence to guide pacing strategy selection in this patient cohort.

Being tested
Left bundle branch area pacing, Conventional pacing strategy
Keywords
Conduction system pacing, Atrioventricular block, After cardiac surgery, Left bundle branch area pacing
Medical subject headings
Atrioventricular Block

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Left bundle branch area pacingDevice

    Conventional pacing strategy versus conduction system pacing strategy in the form of left bundle branch area pacing

  • Conventional pacing strategyDevice

    Conventional pacing strategy

Study groups in NCT07795541
Study groupRoleWhat they receive
Conventional pacing strategyActive comparatorThis arm will receive a conventional pacemaker lead if they have atrioventricular block after cardiac surgery
Receives: Device: Conventional pacing strategy
Left bundle branch area pacing strategyExperimentalThis arm will receive a left bundle branch area pacing pacemaker lead if they have atrioventricular block after cardiac surgery
Receives: Device: Left bundle branch area pacing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in left ventricular ejection fraction

    Change in left ventricular ejection fraction between enrollment and end of follow-up

    Measured: 1 year

Secondary outcomes (6)
  1. Change in left ventricular end-diastolic diameter

    Change in LVEDD from enrollment to end of study follow-up

    Measured: 1 year

  2. Clinical endpoints - composite

    Composite of all-cause mortality, heart failure hospitalization, device-related hospitalization

    Measured: 1 year

  3. All-cause mortality

    All-cause mortality

    Measured: 1 year

  4. Heart failure hospitalization

    Heart failure hospitalization

    Measured: 1 year

  5. Device-related hospitalization

    Device-related hospitalization

    Measured: 1 year

  6. Quality-of-life measurement

    Quality-of-life measurement by standardized questionnaire

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Aug 2026
  2. Study start10 Sep 2026 (estimated)
  3. Primary completionDec 2030 (estimated)
  4. Study completionDec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
110 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07795541
Sponsor's protocol ID
2025-08652-01
Other IDs
20241208, ALFGBG-977905, ALFGBG-1029431, 2025
Acronym
OPTI-PACS
Status last verified
Aug 2026
First submitted
26 Aug 2026
Last updated
31 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Left bundle branch area pacing and Conventional pacing strategy in people with Atrioventricular Block and Cardiac Surgery, run by Sahlgrenska University Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Andreas S Martinsson, MD, PhD (+46313427717, andreas.s.martinsson@vgregion.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in left ventricular ejection fraction (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in